A good night’s sleep isn’t just about the number of hours you log. Getting quality sleep — the kind that leaves you feeling ...

In a comprehensive Genomic Press Commentary published today, researchers have identified what could be the first reliable biomarker for depression risk, potentially transforming how this devastating ...

A 31-year-old woman from Manchester has died from posterior cortical atrophy, a rare, progressive neurodegenerative disorder ...

A woman who passed away as a result of being diagnosed with PCA didn't necessarily show 'tell-tale signs,' with her family ...

Hypertension and other health risks accelerate brain aging, as shown in a 16-year study using MRI data and predictive ...

Young-onset Alzheimer’s affects individuals under 65, leading to memory loss, confusion, and personality changes. Early ...

ATH434 is designed to reduce α-synuclein aggregation and oxidative stress by binding to and redistributing excess loosely bound iron in the brain.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity ...

Researchers have found that increasing physical activity levels around ages 45 to 65 may be linked to lower levels of ...

As these neurons degenerate and die, the signals from the brain are unable to transmit messages to muscles, leading to muscle ...